Development or evaluation of technologies for improving clinical research in Diabetes and Digestive and Kidney Diseases, including technologies for improving data collection and reporting of patient outcomes. Development or evaluation of informatics, or internet-based technologies for biomedical –omics, research or clinical applications in diagnosing or managing Diabetes and Digestive and Kidney Diseases. Development or evaluation of technologies to prevent or cell or tissue injury during other disease states or surgical procedures. (NIDA) 1. Drug (Medication) discovery and development-enabling activities for Substance Use Disorders (SUDs). Innovative in in situ, or in vivo tools for the analysis of the central nervous system, normal and/or diseased. Technologies, including molecular imaging, gene expression profiling, and genotyping and sequencing approaches designed to better inform SUD diagnosis and treatment. Assay development (e.g., biochemical, functional) and validation, especially, hiPSC-based assays, human organoid, or 3-D culture systems with the intention of developing medium to throughput assays. Tools to simplify the design and preclinical development of medications for SUDs. Discovery of SUD-related biomarkers (BMs) (e.g., BMs of chronic drug exposure, pharmacodynamic, toxicological/safety; BM assay development and validation), and device development. Development of BM known to be associated with a health (salutary) outcome, which are quantitatively affected by reduction in drug use are particularly welcome Predictors of clinical outcomes in SUDs, e.g. physiological, electroencephalographic, cognitive tests, and biochemical, epigenetic, and genetic assays. Point of care monitoring systems to improve quantitative assessment of subject adherence to clinical protocols Tools that could be used as quantitative direct (e.g. plasma, saliva, or urine) measures or indirect (e.g. physiological, facial, motor, pupillometry) BMs of drug intoxication. Drug (Medication) discovery and development activities. Application of emerging and existing technologies and platforms for SUD medication development with the focus on products with the potential to minimize drug seeking, compulsive behavior: Early therapeutic discovery activities ranging from Target ID and validation through lead development Preclinical and/or clinical drug development Technologies or formulations to improve medication delivery
Development or evaluation of technologies for improving clinical research in Diabetes and Digestive and Kidney Diseases, including technologies for improving data collection and reporting of patient outcomes. Development or evaluation of –omics, informatics, or internet-based technologies for biomedical research or clinical applications in diagnosing or managing Diabetes and Digestive and Kidney Diseases. Development or evaluation of technologies to prevent or cell or tissue injury during other disease states or surgical procedures. (NIDA) 1. Drug (Medication) discovery and development-enabling activities for Substance Use Disorders (SUDs). Innovative in in situ, or in vivo tools for the analysis of the central nervous system, normal and/or diseased. Technologies, including molecular imaging, gene expression profiling, and genotyping and sequencing approaches designed to better inform SUD diagnosis and treatment. Assay development (e.g., biochemical, functional) and validation, especially, hiPSC-based assays, human organoid, or 3-D culture systems with the intention of developing medium to assays. Tools to simplify the design and preclinical development of medications for SUDs. Discovery of SUD-related biomarkers (BMs) (e.g., BMs of chronic drug exposure, pharmacodynamic, toxicological/safety; BM assay development and validation), and device development. Development of BM known to be associated with a health (salutary) outcome, which are quantitatively affected by reduction in drug use are particularly welcome Predictors of clinical outcomes in SUDs, e.g. physiological, electroencephalographic, cognitive tests, and biochemical, epigenetic, and genetic assays. Point of care monitoring systems to improve quantitative assessment of subject adherence to clinical protocols Tools that could be used as quantitative direct (e.g. plasma, saliva, or urine) measures or indirect (e.g. physiological, facial, motor, pupillometry) BMs of drug intoxication. Drug (Medication) discovery and development activities. Application of emerging and existing technologies and platforms for SUD medication development with the focus on products with the potential to minimize drug seeking, compulsive behavior: Early therapeutic discovery activities ranging from Target ID and validation through lead development Preclinical and/or clinical drug development Technologies or formulations to improve medication delivery throughput
NIH_Topics_for_Budget_Waivers.docx